Zhejiang Wecome Pharmaceutical Company Limited (300878.SZ)
CNY 18.41
(-1.13%)
CNY 18.41
(-1.13%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 519.62 Million CNY | -2.2% |
| 2022 | 531.29 Million CNY | -16.06% |
| 2021 | 632.95 Million CNY | 1.64% |
| 2020 | 622.76 Million CNY | -2.97% |
| 2019 | 641.8 Million CNY | 11.11% |
| 2018 | 577.65 Million CNY | 42.09% |
| 2017 | 406.52 Million CNY | 44.11% |
| 2016 | 282.09 Million CNY | 35.79% |
| 2015 | 207.74 Million CNY | 35.53% |
| 2014 | 153.27 Million CNY | 13.49% |
| 2013 | 135.05 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 96.17 Million CNY | -51.9% |
| 2024 Q3 | 73.86 Million CNY | -23.2% |
| 2024 Q1 | 199.95 Million CNY | 128.21% |
| 2023 Q2 | 120.69 Million CNY | -38.34% |
| 2023 Q1 | 195.73 Million CNY | 243.75% |
| 2023 FY | 519.62 Million CNY | -2.2% |
| 2023 Q4 | 87.61 Million CNY | -24.18% |
| 2023 Q3 | 115.56 Million CNY | -4.26% |
| 2022 Q4 | 56.94 Million CNY | -68.14% |
| 2022 Q3 | 178.72 Million CNY | 59.81% |
| 2022 Q2 | 111.83 Million CNY | -39.15% |
| 2022 Q1 | 183.78 Million CNY | 39.72% |
| 2022 FY | 531.29 Million CNY | -16.06% |
| 2021 Q4 | 131.54 Million CNY | -22.43% |
| 2021 Q1 | 132.25 Million CNY | -12.05% |
| 2021 FY | 632.95 Million CNY | 1.64% |
| 2021 Q2 | 199.57 Million CNY | 50.89% |
| 2021 Q3 | 169.58 Million CNY | -15.03% |
| 2020 Q2 | 183.78 Million CNY | 49.71% |
| 2020 Q1 | 122.75 Million CNY | -34.53% |
| 2020 Q3 | 165.85 Million CNY | -9.75% |
| 2020 Q4 | 150.37 Million CNY | -9.33% |
| 2020 FY | 622.76 Million CNY | -2.97% |
| 2019 Q4 | 187.51 Million CNY | 22.16% |
| 2019 FY | 641.8 Million CNY | 11.11% |
| 2019 Q3 | 153.49 Million CNY | 2.06% |
| 2019 Q2 | 150.39 Million CNY | -0.0% |
| 2019 Q1 | 150.39 Million CNY | 0.0% |
| 2018 FY | 577.65 Million CNY | 42.09% |
| 2017 FY | 406.52 Million CNY | 44.11% |
| 2016 FY | 282.09 Million CNY | 35.79% |
| 2015 FY | 207.74 Million CNY | 35.53% |
| 2014 FY | 153.27 Million CNY | 13.49% |
| 2013 FY | 135.05 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Lifecome Biochemistry Co.,Ltd. | 507 Million CNY | -2.488% |
| Chengdu Kanghua Biological Products Co., Ltd. | 1.56 Billion CNY | 66.853% |
| NanHua Bio-medicine Co., Ltd | 136.79 Million CNY | -279.865% |
| Shandong Sito Bio-technology Co., Ltd. | 1.27 Billion CNY | 59.398% |
| Porton Pharma Solutions Ltd. | 3.66 Billion CNY | 85.831% |
| Guangdong VTR Bio-Tech Co., Ltd. | 796.02 Million CNY | 34.723% |